An international team of researchers, led by investigators at the University of California (UC) Irvine, has uncovered a new type of skeletal tissue that could transform the field of regenerative medicine and tissue engineering. Known as “lipocartilage,” this tissue is found in mammals’ ears, noses, and throats, and has unique…

Pluripotent stem cell (PSC) therapies have shown great promise across a number of diseases, including heart disease, diabetes, and cystic fibrosis, but have been plagued by them often leading to cancer after transplantation. Now, a team of researchers from the Nara Institute of Science and Technology in Japan have identified…

Life is like the changing of seasons, each uniquely beautiful. Just as autumn leaves fall to the ground and make way for winter’s gentle snow, life has transformational cycles. The cycle of life continues through the changing seasons, like how the autumn winds strip the trees of their leaves and…

A multidisciplinary team at UC San Diego Health, participating in a clinical trial sponsored by Neurona Therapeutics, recently injected regenerative brains cells into the brain of a patient in an effort to treat their epileptic seizures. The regenerative brain cell therapy uses interneurons derived from human stems cells and has…

By Anuj Kalsy   Sponsored content brought to you by Repairing tissues and organs makes up a key goal of medicine, and many companies pursue this objective. By 2030, the regenerative-medicine market is projected to reach nearly $38 billion, based on an annual growth rate of more than 15% a…

In vivo reprogramming therapy company Mogrify and Astellas Pharma, a developer of regenerative medicines, today announced a collaboration to combine their approaches to therapy development to discover and develop in vivo regenerative medicine treatment approaches to address sensorineural hearing loss (SNHL). SNHL is caused by damage to the structures to…

Enzyvant, a subsidiary of Sumitovant Biopharma, received a long-awaited FDA approval for its tissue based regenerative therapy for treatment of congenital athymia last week after almost 30 years of development. The treatment, which is known as Rethymic, is a single use therapy that is inserted as small slices of tissue…

A task force of the Alliance for Regenerative Medicine (ARM) consisting of gene-editing therapy developers today sided with the emerging scientific consensus against germline gene editing in human clinical research without coming to terms with legal, ethical, and other implications—part of a statement intended to articulate a bioethical framework for…

Aspect Biosystems, which develops bioprinted tissue therapeutics for regenerative medicine, has announced that it has closed a U.S. $115M Series B financing round. Proceeds will accelerate advancement of Aspect’s pipeline and advance Aspect’s full-stack tissue therapeutic platform. The round was led by Dimension, a multistage investment firm “dedicated to the…

Patient-derived tumor organoids have been leveraged for disease modeling and preclinical studies but rarely applied in real time to aid with interpretation of patient treatment responses in clinics. Now, researchers at the Perelman School of Medicine at the University of Pennsylvania have for the first time used lab-grown organoids created…

A team of researchers led by the Berlin Institute for Medical Systems Biology of the Max Delbrück Center (MDC-BIMSB) and Charité – Universitätsmedizin, have shed new light on the role of the p53 tumor suppressor gene in the pathogenesis of ulcerative colitis (UC). The collective findings from the researchers’ studies…

Children diagnosed with Canavan disease, who have always faced a grim prognosis—the inability to speak, walk, or maintain head control for their short lifespans with this fatal rare neurodegenerative disorder—may soon be treatable, even “curable.” At the 31st annual European Society for Cell and Gene Therapy (ESCGT) meeting, BridgeBio presented…

Researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA say they have engineered a novel experimental drug that may enhance heart repair following a heart attack, with the potential to reduce the incidence of heart failure in patients. The new drug, details…

Researchers from the University of California, Los Angeles (UCLA) have unveiled a new tool consisting of graphene oxide with attached antibodies that allows engineered CAR-T cells to more closely mimic the natural interactions between immune cells, effectively boosting the therapy’s cancer-fighting attributes. This innovation, reported recently in the journal Nature…

A 25-year old woman has become the first person to be treated for type 1 diabetes using cells extracted from her own body—an allogeneic transplant. She started producing her own insulin less than three months after receiving a transplant of reprogrammed stem cells. In a notable change from standard practice.…